Physician profile
Christopher Sinclair
NPI 1205987351
$12,399.65
in general payments reported to CMS, 2019-2025
48 companies · $8,812 in 2025
The $8,812 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,519 · 2020: $37.19 · 2022: $224 · 2023: $644 · 2024: $164 · 2025: $8,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,613 · Food and Beverage: $1,874 · Travel and Lodging: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,612.50 |
| Food and Beverage | $1,873.57 |
| Travel and Lodging | $1,133.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $8,346.25 | 2025 | Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $552.96 | 2019-2022 | |
| Biogen, INC. | $446.96 | 2019-2025 | Vumerity, Tysabri |
| Amgen INC. | $400.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $159.37 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $152.25 | 2019 | |
| Sunovion Pharmaceuticals INC. | $150.17 | 2019 | |
| Ucb, INC. | $138.84 | 2019-2025 | Nayzilam |
| Genzyme Corporation | $137.77 | 2019 | |
| Neurelis, INC. | $125.00 | 2025 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $117.94 | 2025 | Hyqvia |
| Acadia Pharmaceuticals INC | $113.63 | 2019-2023 | Nuplazid |
| Celgene Corporation | $113.44 | 2022-2023 | Zeposia |
| Genentech USA, INC. | $99.62 | 2019-2023 | Enspryng, Ocrevus |
| Neurocrine Biosciences, INC. | $77.78 | 2019 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.